Resolve Therapeutics is pioneering safe, targeted therapies for underserved patients with autoimmune diseases. Our lead program, RSLV-132, is designed to prevent chronic, systemic inflammation that may cause organ damage and the symptoms associated with autoimmune diseases. RSLV-132 is a first-in-class RNase-Fc fusion protein being developed to treat patients with lupus and Sjögren’s syndrome. We have successfully completed a Phase 2a study in SLE (insert link to Dec 8, 2020 press release) and will be initiating a Phase 3 study in Sjögren’s syndrome in 2022.
Chief Executive Officer Member,
Board of Managers
James Posada, Ph.D., is founder and Chief Executive Officer…
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical…